ReviewMolecular cancer2026
Artificial intelligence models: transforming early diagnosis and precise treatment of gastrointestinal cancers.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomarkers in Gastric Cancer: Blood Biomarkers, Liquid Biopsy, Artificial Intelligence, and Risk-Stratified Care.Cancers · 2026Review
- Interpretable Machine Learning Models Based on Blood Cell-Derived Inflammatory Indices for Identifying Colorectal Neoplasia: A Retrospective Study.Journal of inflammation research · 2026Article
- Artificial intelligence in gastric cancer research: a bibliometric and visualized analysis from 1993 to 2026.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Artificial intelligence (AI) has become an integral force in the clinical landscape of gastrointestinal (GI) oncology. Recent advances in model architectures ranging from traditional machine learning and convolutional neural networks (CNNs) to transformer-based foundational models and graph neural networks (GNNs) have enabled the extraction of complex features from diverse data modalities, including endoscopic images, radiology, pathology whole-slide images, and multi-omics profiles. In this review, AI models are systematically classified into supervised learning, unsupervised clustering, multimodal fusion, and interpretable modeling. The advantages of each model are delineated in unravelling tumor heterogeneity, anatomical characteristics, and treatment-relevant biomarkers. Furthermore, three types of clinical application are emphasized: (1) early screening and lesion localization via segmentation or anomaly detection; (2) molecular subtyping and patient stratification for diagnosis with risk assessment; (3) therapy guidance through response prediction and personalized treatment planning. We also discuss major challenges on the application of AI in integration of heterogeneous clinical data, model generalizability across centers, and the interpretability of predictions. Collectively, this review highlights the transformative potential of AI in better understanding tumor biology and its clinical value in advancing personalized medicine for GI cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.